Venus Remedies’ Vancoplus gets patent from Australia

10 Apr 2012 Evaluate

Venus Remedies has added one more patent to its kitty for Vancoplus, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. After Potentox, this is the company’s second patent grant from the Australian Patent office (APO), Government of Australia, and is valid till February 2026.

The total market size of MRSA in the world accounts for $9 billion. At present, it is growing at CAGR of 4.8 percent which is estimated to reach $12.40 billion by 2017. The company expects to grab a fair share of this market within 3 years of launch of its novel research product Vancoplus in all major territories of the world.

Vancoplus, a strategically designed formulation through CVMC technology, is the landmark achievement of Venus Medical Research Center Team. The formulation is the most effective and safe option available in the market to curb the notorious methicillin resistant staphylococcus.

Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×